Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells $27,915.72 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 3,507 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $7.96, for a total value of $27,915.72. Following the completion of the sale, the insider directly owned 155,142 shares in the company, valued at approximately $1,234,930.32. The trade was a 2.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

James Peyer also recently made the following trade(s):

• On Monday, December 8th, James Peyer sold 3,105 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $8.59, for a total value of $26,671.95.
• On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $187,392.50.
• On Thursday, December 4th, James Peyer sold 5,000 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $9.06, for a total transaction of $45,300.00.

Sensei Biotherapeutics Price Performance

SNSE traded up $0.70 on Wednesday, hitting $8.67. The company had a trading volume of 41,996 shares, compared to its average volume of 62,977. The stock has a fifty day simple moving average of $9.86 and a 200-day simple moving average of $8.63. The firm has a market capitalization of $10.92 million, a P/E ratio of -0.45 and a beta of 0.32. Sensei Biotherapeutics, Inc. has a 52-week low of $5.00 and a 52-week high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, November 14th. The company reported ($3.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.11) by $0.49. Equities research analysts expect that Sensei Biotherapeutics, Inc. will post -1.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNSE has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Sensei Biotherapeutics in a research report on Monday. HC Wainwright lowered shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.